Orthofix Medical stock gains on Q2 revenue beat
Published on 10/05/2026 at 16:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Orthofix Medical (ISIN US68752M1080) was trading at USD 9.27 on Nasdaq at 10:27 a.m. ET on October 5, 2026, up 1.98 percent from the prior close. The move puts the medical device maker near the lower end of its USD 8.50 to USD 16.99 52-week range, while its second-quarter revenue beat expectations.
Q2 revenue beat consensus
Orthofix reported USD 210.93 million of revenue for the second quarter of 2026, compared with the USD 209.28 million consensus estimate, according to MarketBeat on September 16, 2026. The USD 1.65 million revenue difference equals a 0.8 percent beat.
The adjusted loss was USD 0.39 per share, better than the USD 0.41 consensus loss by USD 0.02. Net loss reached USD 15.8 million for the quarter, leaving profitability as the central operating issue despite the revenue performance.
Losses keep pressure on execution
Orthofix describes its business as a medical technology portfolio spanning spine implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies such as the 7D FLASH Navigation System, according to Orthofix Medical. The company serves complex musculoskeletal cases through products intended to support healing and restore mobility.
MarketBeat reported a negative net margin of 7.41 percent after the second-quarter release and cited a full-year consensus loss of USD 1.29 per share. That combination gives the revenue beat limited room to change the investment case until sales growth is accompanied by narrower losses.
The companys balance between spine and limb reconstruction also matters because its products reach hospitals, healthcare organizations, surgeons and ambulatory care providers. The portfolio offers several revenue channels, but the second-quarter net loss shows that scale has not yet translated into consistent earnings.
Analysts see a wider valuation gap
Five brokerages give Orthofix an average Hold rating, with three Buy ratings, one Hold and one Sell. The consensus price target is USD 14.75, so the current USD 9.27 price lies 37.2 percent below that target, according to MarketBeat on October 1, 2026.
The consensus is balanced rather than uniformly bullish. For investors, the key test is whether the revenue trajectory can reduce the USD 15.8 million quarterly loss while the stock remains close to its 52-week low.
OFIX trades at USD 9.27
Orthofix Medical was trading at USD 9.27 on Nasdaq at 10:27 a.m. ET on October 5, 2026, with a market capitalization of USD 374.7 million and volume of 38,601 shares.
Orthofix Medical stock facts
- Company: Orthofix Medical Inc.
- ISIN: US68752M1080
- Ticker: OFIX
- Trading venue: NASDAQ
- Price as of October 5, 2026, 10:27 a.m. ET: USD 9.27
- Market capitalization: USD 374.7 million (as of October 5, 2026)
- 52-week range: USD 8.50-16.99 (as of October 5, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Volume: 38,601 shares (as of October 5, 2026)
